GlaxoSmithKline Pharmaceuticals
Market Cap
₹263.4b
Last Updated
2020/12/01 12:18 UTC
Data Sources
Company Financials +
Executive Summary
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has GlaxoSmithKline Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 500660 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 500660's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
1.8%
500660
2.1%
IN Pharmaceuticals
1.2%
IN Market
1 Year Return
-8.0%
500660
51.2%
IN Pharmaceuticals
10.4%
IN Market
Return vs Industry: 500660 underperformed the Indian Pharmaceuticals industry which returned 48.5% over the past year.
Return vs Market: 500660 underperformed the Indian Market which returned 8.3% over the past year.
Shareholder returns
| 500660 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.8% | 2.1% | 1.2% |
| 30 Day | 5.9% | 5.9% | 12.1% |
| 90 Day | -1.5% | 6.4% | 12.6% |
| 1 Year | -5.6%-8.0% | 53.0%51.2% | 12.4%10.4% |
| 3 Year | 33.0%25.8% | 43.1%39.6% | 10.0%4.6% |
| 5 Year | 3.2%-4.9% | 12.1%8.2% | 59.8%47.8% |
Long-Term Price Volatility Vs. Market
How volatile is GlaxoSmithKline Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 years ago | Simply Wall St
Is It Time To Sell GlaxoSmithkline Pharmaceuticals Limited (BOM:500660) Based Off Its PE Ratio?Valuation
Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
19.83x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 500660 (₹1552.05) is trading above our estimate of fair value (₹486.55)
Significantly Below Fair Value: 500660 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500660 is unprofitable, so we can't compare its PE Ratio to the IN Pharmaceuticals industry average.
PE vs Market: 500660 is unprofitable, so we can't compare its PE Ratio to the Indian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500660's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500660 is overvalued based on its PB Ratio (19.8x) compared to the IN Pharmaceuticals industry average (2.2x).
Next Steps
Future Growth
How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
32.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 500660 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.2%).
Earnings vs Market: 500660 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 500660's is expected to become profitable in the next 3 years.
Revenue vs Market: 500660's revenue (10.6% per year) is forecast to grow slower than the Indian market (11.5% per year).
High Growth Revenue: 500660's revenue (10.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 500660's Return on Equity is forecast to be high in 3 years time (31.4%)
Next Steps
Past Performance
How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?
-23.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500660 is currently unprofitable.
Growing Profit Margin: 500660 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 500660 is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare 500660's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 500660 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26%).
Return on Equity
High ROE: 500660 has a negative Return on Equity (-25.3%), as it is currently unprofitable.
Next Steps
Financial Health
How is GlaxoSmithKline Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 500660's short term assets (₹17.9B) exceed its short term liabilities (₹11.1B).
Long Term Liabilities: 500660's short term assets (₹17.9B) exceed its long term liabilities (₹3.0B).
Debt to Equity History and Analysis
Debt Level: 500660 is debt free.
Reducing Debt: 500660 has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.
Debt Coverage: 500660 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 500660 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?
1.29%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500660's dividend (1.29%) is higher than the bottom 25% of dividend payers in the Indian market (0.52%).
High Dividend: 500660's dividend (1.29%) is low compared to the top 25% of dividend payers in the Indian market (2.1%).
Stability and Growth of Payments
Stable Dividend: 500660's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500660's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: 500660 is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: 500660's dividends in 3 years are forecast to be covered by earnings (69.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Sridhar Venkatesh
0.58
Tenure
Mr. Sridhar Venkatesh serves as Managing Director at GlaxoSmithkline Pharmaceuticals Limited since April 1, 2020. Mr. Venkatesh served as the Commercial Head of Pharmaceuticals at GlaxoSmithkline Pharmaceu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| South Asia Finance Director | 2.83yrs | ₹43.38m | no data | |
| Executive Director of Technical | 9.25yrs | ₹28.94m | no data | |
| VP of Administration & Real Estate and Company Secretary | no data | ₹13.24m | no data | |
| Executive Vice President of Human Resources | 3yrs | ₹41.34m | no data | |
| Chief Commercial Officer of Pharmaceuticals | 3.17yrs | ₹45.42m | no data | |
| Managing Director | 0.58yr | no data | no data | |
| Vice President of Ethics & Compliance | 2.08yrs | no data | no data | |
| Executive Vice President of Legal | 0.67yr | no data | no data | |
| Vice President of Communications & Government Affairs | 3.58yrs | no data | no data | |
| Executive Vice President of Vaccines | 3.58yrs | no data | no data | |
| Executive Vice-President of Regulatory Affairs | no data | no data | no data | |
| Regional Quality Head South Asia & Vice President of Quality | 2.75yrs | no data | no data |
2.9yrs
Average Tenure
Experienced Management: 500660's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| South Asia Finance Director | 2.83yrs | ₹43.38m | no data | |
| Executive Director of Technical | 9.25yrs | ₹28.94m | no data | |
| Managing Director | 0.58yr | no data | no data | |
| Independent Chairperson | 1.58yrs | ₹2.90m | 0.00035% ₹ 922.1k | |
| Non-Executive Independent Director | 15.33yrs | ₹2.25m | no data | |
| Non-Executive Independent Director | 11.33yrs | ₹2.10m | no data | |
| Non Executive Director | 3.58yrs | no data | no data | |
| Non-Executive Independent Director | 10.08yrs | ₹2.20m | no data | |
| Non-Executive Independent Director | 9yrs | ₹1.80m | no data | |
| Additional Independent Director | 0.50yr | no data | no data |
6.3yrs
Average Tenure
67.5yo
Average Age
Experienced Board: 500660's board of directors are considered experienced (6.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
GlaxoSmithKline Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: GlaxoSmithKline Pharmaceuticals Limited
- Ticker: 500660
- Exchange: BSE
- Founded: 1924
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹263.443b
- Shares outstanding: 169.41m
- Website: https://www.india-pharma.gsk.com
Number of Employees
Location
- GlaxoSmithKline Pharmaceuticals Limited
- GSK House
- Dr. Annie Besant Road
- Mumbai
- Maharashtra
- 400030
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 500660 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Jun 1996 |
| GLAXO | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Jun 1996 |
Biography
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescript...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/12/01 12:18 |
| End of Day Share Price | 2020/12/01 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.